Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Typing in Advanced Thyroid Cancer
NCT06195228Phase 4Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2020
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 4 trial of dabrafenib + trametinib, trametinib, entrectinib, larotrectinib, pralsetinib in thyroid cancer, sponsored by Fudan University. Started Jan 2020; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinibentrectiniblarotrectinibpralsetinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT06195228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195228.